OmniAb SPAC Presentation Deck
THE OMNIAB PLATFORM
Antibody Generation
Technologies
Computational
Antigen Design &
Proprietary Reagents
mniRat mniMouse
OmniChicken
Robust Antibodies for Any Target
OmniFlic
OmniClic
OmniTaur
Cow-inspired
Bispecific Antibody Antibodies for Difficult
Targets
Generation
Create Diverse
Antibody Pools
Screen Antibody
Candidates
(1) In August 2021, zimberelimab, was approved in China for the treatment of recurrent or refractory classical Hodgkin's lymphoma, and in December 2021
sugemalimab, was approved in China for the first-line treatment of metastatic (stage IV) non-small cell lung cancer in combination with chemotherapy.
Identify the
Right Antibody
We believe generating large and diverse pools of high-quality
antibodies increases the likelihood of discovering the antibody with
the most desirable therapeutic characteristics
Industry's only four-species platform
23 in clinical development and two approved antibodies (1)
A heritage of genetic engineering advancements
Carefully designed transgenes for robust response
Bispecific and cow-inspired technologies enable next
generation therapeutics
16
OmniAbView entire presentation